Recent research have converged on the intersection of glucagon-like peptide-1|GIP|GCGR agonist therapies and DA signaling. While GIP stimulators are commonly employed for addressing type 2 T2DM, their potential consequences on reinforcement circuits, specifically influenced by dopamine pathways, are receiving substantial attention. This report deta